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Abstract
Malaria is a major health burden in sub-Saharan African countries, including Mali. The disease is complex, with multiple
genetic determinants influencing the observed variation in response to infection, progression, and severity. We assess the
influence of sixty-four candidate loci, including the sickle cell polymorphism (HbS), on severe malaria in a case-control study
consisting of over 900 individuals from Bamako, Mali. We confirm the known protective effects of the blood group O and
the HbS AS genotype on life-threatening malaria. In addition, our analysis revealed a marginal susceptibility effect for the
CD40 ligand (CD40L)+220C allele. The lack of statistical evidence for other candidates may demonstrate the need for large-
scale genome-wide association studies in malaria to discover new polymorphisms. It also demonstrates the need for
establishing the region-specific repertoire of functional variation in important genes, including the glucose-6-phosphatase
deficiency gene, before embarking on focused genotyping.
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Introduction
Malaria is a life-threatening parasitic disease transmitted by
mosquitoes. Despite the concerted and renewed efforts to control
the disease, it still persists as a major health burden, being
responsible for 655,000 deaths in 2010, mainly children in Sub-
Sahara Africa [1]. In Mali, there are over 800,000 recorded cases
of malaria among its ,14 million people every year, and it
accounts for 17 percent of child deaths [1]. Malaria is a complex
disease with many genetic and environmental determinants
influencing the observed variation in response to infection,
progression and severity. Several factors are important for these
different phenotypes observed, such as parasite genetic make-up,
and host age, state of immunity and genetic background [2]. It has
been estimated that 25% of the total variation in mild and severe
malaria in a Kenya cohort was explained by host genes [2]. The
different geographic distributions of sickle-cell disease, a thalasse-
mia, glucose-6-phosphatase deficiency (G6PD), ovalocytosis, and
the Duffy-negative blood group are examples of the general
principle that different populations have evolved different genetic
variants to protect against malaria (see [3], for a review). The most
striking example is the beta-globin HBB gene, in which three
different coding SNPs confer protection against malaria: Glu6Val
(HbS), Glu6Lys (HbC), and Glu26Lys (HbE). The HbS allele is
common in Africa but rare in Southeast Asia, whereas the opposite
is true for the HbE allele. However, a more complex picture
emerges at the local level, exemplified by the Dogon people of
Mali, who have a much lower frequency of the HbS allele than do
most other West African groups and instead have a high frequency
of the HbC allele [4]. Striking differences in response to malaria
infection have also been observed among ethnic groups who live in
the same geographical region. For example, it has been observed
that the Fulani of Burkina Faso [5] and of Mali [6] have a
significantly lower prevalence of malaria parasitaemia and fewer
malaria clinical attacks, when compared to other ethnic groups
living in neighbouring villages. In addition to the sickle polymor-
phism (HbS) [7], G6PD (reviewed in [8]), and ABO blood group
[9,10], a number of candidate polymorphisms have been proposed
for the reduced risk of severe malaria. For example, these include
genes that are relevant to immunity and inflammation such as the
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tumour necrosis factor (TNF, MHC class III region, reviewed in
[11]), Toll-like receptors (TLR-4,9) [12], CD40 ligand (CD40L)
[13], the interferon gamma (IFNG) (reviewed in [14], and the
Nitric oxide synthase type 2 (NOS2A) genes (reviewed in [15].
Here we investigate whether a number malaria candidate SNPs,
including the HbC, HbS and ABO, are associated with severe
malaria. Our study is the first to survey malaria candidate SNPs in
a Malian population, and we seek to confirm genetic associations
found in other studies. We consider a cohort of over 900
individuals recruited in Bamako, predominantly from the Bam-
bara ethnicity, which is under-represented in other genetic
epidemiological studies in Western Africa.
Methods
Participants, Materials and Methods
Ethics Statement. This study was approved by the Faculty of
Medicine, Pharmacy and Dentistry (University of Bamako) Ethics
Review Committee. All clinical and biological samples were
collected and DNA was genotyped following approval by this
committee. Written informed consent was obtained from the next
of kin, carers or guardians on the behalf of the minors/children
participants involved in this study.
Study participants. Patient samples were collected as part of
ongoing epidemiological studies of severe malaria at the Centre
Hospitalier Universitaire Gabriel Toure, Bamako, Mali (malaria
cases 541 (57.9%); healthy controls 393 (42.1%)). They had a
median age of ,3 years, and were predominantly from the
Bambara ethnic group (53%) (see Table 1).
Phenotypic definition. All cases were children admitted to
hospital with evidence of P. falciparum on blood film and clinical
features of uncomplicated and severe malaria [16,17]. Subjects
were defined as having had cerebral malaria (CM) if their Blantyre
coma score was less than or equal to 2 on presentation or early
during admission. A second phenotypic subset of severe malarial
anaemia (SMA) was defined as those subjects having had a
haemoglobin concentration of less than 5 g/dl or a haematocrit
less than 15%. Participants with co-existing severe or chronic
medical conditions (e.g. bacterial pneumonia, kwashiorkor)
unrelated to a severe malarial infection were excluded. Most
cases had severe malaria (n = 458, 84.7%), but a minority had
uncomplicated conditions (n = 83, 15.3%) (see Table 1). Controls
were healthy individuals matched for age, ethnicity and residence
to severe malaria cases (Table 1). For the purpose of analysis, we
either excluded uncomplicated malaria cases or included them as
part of the control group. Because of restrictions in sample size, we
do not present an analysis on different ethnic groups or specific
sub-clinical phenotypes.
Sample preparation and genotyping. Genomic DNA
samples underwent whole genome amplification through Primer
Extension Pre-amplification (PEP) [18], before genotyping on a
Sequenom MassArray genotyping platform [19,20]. Sixty-four
malaria candidate SNPs were genotyped, including: Haemoglobin
variants C (HbC, rs33930165) and S (HbS, rs334), plus two SNPs
that allow an estimate of the ABO blood group [10]. The
rs8176719 derived allele results in a non-functional enzyme, and
group O individuals are DD, while non-O Individuals are either II
or ID. In addition, rs8176746 is involved in the enzyme’s substrate
selection and therefore defines either the A or B blood groups. The
two Sequenom iPLEX reactions designed also included gender-
typing SNPs. The selection of SNPs for genotyping was
undertaken by the MalariaGEN Consortium, and were selected
by interrogation of the literature and ongoing consortial experi-
ments for evidence of association with severe malaria. Full details
of polymorphisms can be found at www.malariagen.net, and a list
of SNPs typed can also be found in Tables 2 and S1.
Statistical analysis. Genotypic deviations from Hardy-
Weinberg equilibrium (HWE) were assessed using a chi-square
statistical test. SNPs were excluded from analysis if they had at
least 10% of genotype calls missing or there was significant
deviation from HWE (p,0.001). Case-control association analysis
using SNP alleles/genotypes was undertaken by logistic regression
and included the covariates: ethnic group and the HbS
polymorphism. In this approach we modelled the SNP of interest
assuming several related genotypic mechanisms (additive, domi-
nant, recessive, heterozygous advantage and general models) and
reported the minimum p-value from these correlated tests. All
analyses were performed using the R statistical package (http://
www.r-project.org). Performing multiple statistical tests leads to
inflation in the occurrence of false positives and using a
permutation approach that accounted for correlation between
markers and tests, we estimated a p-value cut-off of 0.002 to be
statistically significant. Allele frequency differences were estimated
using the Fst metric, with values potentially varying from zero (no
population differentiation) to one (complete differentiation) [22].
Results
Six SNPs were removed from the analysis because they were
monomorphic (rs33950507, rs5743611, rs2814778), deviated from
HWE in controls (rs2227478, rs2535611) or had high rates of
missing genotype calls (rs1801274). Allelic-based tests revealed
potential associations of HbS polymorphism (rs334, HBB gene),
the O blood group (and its components rs8176746 and
rs8176719), and rs1126535 (CD40L+220) with severe malaria
(P,0.002) (Table 2). Figure 1 shows the minimum p-values from
the genotypic tests applied to the autosomal SNPs, and confirms
that the sickle cell (HbS) and ABO polymorphisms (rs8176746,
rs8176719) are significantly associated with severe malaria. This
Table 1. Baseline and clinical characteristics.
Controls (n=393) Cases (n =541)
Age* (median, range) (38.0) (4.0–178.0) (36.0) (2.0–173.0)
Gender - male 195 49.6% 300 55.5%
Bamako residence 140 35.6% 200 37.0%
Ethnicity
Bambara 219 55.7% 272 50.3%
Malinke 55 14% 83 15.3%
Other 48 12.2% 78 14.4%
Peulh 36 9.2% 56 10.4%
Sarakole 35 8.9% 52 9.6%
Clinical phenotype
Uncomplicated malaria - - 83 15.3%
Any severe malaria - - 458 84.7%
Any SMA - - 304 66.4%
Any CM - - 350 75.1%
Both SMA+CM - - 247 53.0%
Any RD - - 200 42.9%
Malaria death - - 72 15.7%
*in months, SMA= severe malarial anaemia, CM= cerebral malaria,
RD= respiratory distress.
doi:10.1371/journal.pone.0043987.t001
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Table 2. Single nucleotide polymorphisms.
SNP MajA MinA MAF Controls Cases HWE P OR LCL UCL P
rs3024500 G A 0.363 0.367 0.358 0.3800 0.963 0.793 1.170 0.7079
rs1800896 C T 0.332 0.338 0.327 0.4408 0.951 0.781 1.158 0.6151
rs1800890 T A 0.185 0.195 0.175 0.0183 0.875 0.689 1.112 0.2743
rs17047660 G A 0.337 0.331 0.342 0.6354 1.047 0.860 1.275 0.6490
rs17047661 A G 0.219 0.223 0.216 0.5149 0.959 0.766 1.201 0.7182
rs1803632 C G 0.456 0.447 0.465 0.4712 1.075 0.892 1.295 0.4492
rs334 A S 0.024 0.038 0.010 0.6769 0.255 0.122 0.533 0.0003
rs33930165 G A 0.054 0.059 0.049 0.1788 0.824 0.540 1.256 0.3669
rs7935564 G A 0.474 0.479 0.468 0.6407 0.955 0.792 1.152 0.6319
rs542998 T C 0.411 0.436 0.385 0.2672 0.810 0.669 0.980 0.0304
rs2227507 T C 0.022 0.022 0.021 0.6289 0.960 0.509 1.811 0.8994
rs1012356 A T 0.487 0.498 0.475 0.1593 0.912 0.758 1.099 0.3331
rs2227491 T C 0.312 0.314 0.309 0.1876 0.974 0.797 1.190 0.7972
rs2227485 G A 0.486 0.497 0.476 0.4513 0.920 0.764 1.109 0.3814
rs229587 C T 0.286 0.266 0.305 0.3735 1.211 0.981 1.493 0.0742
rs1805015 C T 0.484 0.488 0.479 0.0791 0.966 0.801 1.164 0.7152
rs2230739 G A 0.168 0.167 0.169 0.2478 1.014 0.791 1.300 0.9145
rs10775349 G C 0.163 0.158 0.167 0.9521 1.065 0.828 1.371 0.6229
rs2297518 A G 0.085 0.081 0.090 0.2139 1.112 0.797 1.551 0.5323
rs1800482 C G 0.092 0.089 0.096 0.1582 1.077 0.782 1.484 0.6500
rs9282799 T C 0.067 0.063 0.071 0.0786 1.146 0.791 1.660 0.4722
rs8078340 T C 0.251 0.257 0.245 0.3906 0.939 0.758 1.164 0.5659
rs1799969 G A 0.001 0.001 0.001 0.9812 1.035 0.065 16.566 0.9809
rs5498 G A 0.125 0.124 0.126 0.3716 1.018 0.769 1.348 0.9005
rs373533 T G 0.375 0.354 0.397 0.0643 1.200 0.989 1.456 0.0647
rs461645 T C 0.380 0.360 0.399 0.1011 1.180 0.974 1.429 0.0912
rs17561 T G 0.177 0.178 0.176 0.6004 0.986 0.774 1.257 0.9110
rs1143634 T C 0.120 0.113 0.126 0.4473 1.133 0.848 1.513 0.3977
rs8386 T C 0.146 0.145 0.148 0.3342 1.024 0.788 1.331 0.8578
rs1128127 G A 0.436 0.424 0.448 0.1413 1.102 0.912 1.332 0.3133
rs187084 C T 0.238 0.243 0.232 0.0059 0.944 0.755 1.182 0.6171
rs6780995 G A 0.459 0.455 0.463 0.9004 1.032 0.856 1.244 0.7443
rs708567 G A 0.483 0.462 0.503 0.4465 1.183 0.977 1.431 0.0849
rs4833095 T C 0.085 0.078 0.093 0.3797 1.220 0.873 1.704 0.2450
rs5743810 C T 0.002 0.002 0.001 0.9622 0.503 0.046 5.555 0.5748
rs5743809 T C 0.047 0.041 0.054 0.7487 1.329 0.852 2.073 0.2096
rs2706384 C A 0.435 0.449 0.422 0.0082 0.895 0.739 1.084 0.2579
rs20541 C T 0.176 0.173 0.177 0.3304 1.028 0.789 1.341 0.8361
rs2243250 T C 0.242 0.244 0.240 0.9126 0.979 0.786 1.219 0.8496
rs1801033 A C 0.445 0.432 0.457 0.9663 1.105 0.916 1.333 0.2951
rs1555498 C T 0.436 0.426 0.446 0.3849 1.089 0.903 1.313 0.3740
rs2239704 G T 0.378 0.383 0.372 0.8615 0.951 0.785 1.153 0.6093
rs909253 T C 0.419 0.411 0.426 0.1203 1.063 0.878 1.287 0.5316
rs1799964 T C 0.140 0.144 0.136 0.7781 0.942 0.720 1.232 0.6633
rs1800750 G A 0.014 0.013 0.015 0.7744 1.115 0.506 2.457 0.7876
rs1800629 A G 0.134 0.137 0.131 0.5698 0.947 0.721 1.243 0.6940
rs361525 G A 0.037 0.033 0.040 0.4682 1.242 0.758 2.035 0.3892
rs3093662 G A 0.072 0.067 0.078 0.4503 1.191 0.832 1.706 0.3401
rs2242665 G A 0.264 0.249 0.280 0.8738 1.175 0.950 1.452 0.1364
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genotypic analysis adjusting for the potentially confounding effects
of ethnicity (and where appropriate HbS) supports the heterozy-
gous advantage effect of the HbS-AS genotype (Odds ratio AS vs.
AA: 0.03, P,6e-10), and the reduced risk in the O blood group
(Odds ratio O vs. A/B/AB: 0.58, P= 0.0003) (Table 3). An
increased risk from the CD40L+220-C allele was observed for
males (Odds ratio C vs. A 2.12, P = 0.05) and females (Odds ratio
additive C model 1.67, P= 0.03), and the pooled result was
marginally non-significant (Odds ratio additive C model 1.79,
P = 0.0045) (Table 3). The G6PD-202 polymorphism has been
used as a molecular surrogate for the A- deficiency (see [8,21] for a
review). We found no strong evidence of a G6PD association with
severe malaria risk in males, females or overall (Tables 2 and 3,
P.0.06); the direction of the odds ratios suggests those with the
202-A (A-) allele were at increased (rather than a decreased) risk of
the disease. All our results were insensitive to the inclusion or
exclusion of uncomplicated malaria cases in the control group.
There were no major allele frequency differences between the
Bambara and other ethnic groups (median Fst 0.001, only 3 Fst
values greater than 0.01, maximum 0.015).
Discussion
In our study, we set out to investigate the role of candidate
malaria polymorphisms on severe malaria risk in a predominantly
Bambara population in and around Bamako. To minimise errors
we standardised procedures using case report forms, pre-defined
definitions of severe malaria and sub-clinical phenotypes, and
ensured all samples underwent genotyping on the same Sequenom
MassArray platform with resulting low rates of missing data
(,5%). In addition, all analyses were adjusted for ethnicity,
minimising the confounding effects and potential false positives
arising from population stratification.
Data analysis confirmed the known (,90%) reduced severe
malaria risk from the sickle cell AS genotype [7]. The low
frequency of the S allele in the controls (,3.8%) is in keeping with
other populations (see http://www.map.ox.ac.uk/) in West
(Burkina Faso 5.2%, Cameroon 6.5%, Gambia 7.6%, Ghana
6.5%) and East (Kenya 6.4%, Malawi 2.7%, Tanzania 7.8%)
Africa. The frequency of the HbC allele was 5% in cases and 6%
in controls, both greater than the HbS allele, but there was no
strong evidence of association (P.0.3). The higher frequency of
the HbC allele has been observed in other West African
populations [4].
Our analysis also confirms the known protective effects of the
blood group O on life threatening malaria, which is thought to act
on malaria pathogenesis through the mechanism of reduced P.
falciparum rosetting [9,10]. An insight into an underlying molecular
mechanism could lead to the development of a new anti-malarial
therapy. Our inability to detect associations found in other studies
may be due to previously reported false-positives, and methodo-
logical issues such as variation in phenotype definition, choice of
controls, village surveys versus hospital-based studies, possible
heterogeneity in the parasite population, immune status of
subjects, and study location. There may also be issues with sample
size (statistical power). At the present sample size, we have 90%
1power to detect a dominant odds ratio effect of 1.5 with a minor
allele frequency of 0.20 and type I error of 5%. Reducing the odds
ratio to 1.4 or MAF to 0.13 would lead to 80% power. It is clear
that much larger studies are required to detect more modest
Table 2. Cont.
SNP MajA MinA MAF Controls Cases HWE P OR LCL UCL P
rs17140229 C T 0.393 0.387 0.399 0.7000 1.053 0.869 1.275 0.5988
rs2075820 A G 0.424 0.430 0.418 0.9496 0.954 0.790 1.152 0.6250
rs3211938 G T 0.143 0.157 0.129 0.0345 0.793 0.607 1.037 0.0900
hCD36_G1439C C G 0.055 0.060 0.050 0.7433 1.216 0.805 1.836 0.3520
rs4986790 G A 0.110 0.120 0.100 0.0436 0.819 0.608 1.104 0.1893
rs8176746 A C 0.244 0.213 0.276 0.0093 1.412 1.135 1.757 0.0020
rs8176719 I D 0.403 0.364 0.442 0.8022 1.384 1.145 1.673 0.0008
ABO Non-O O 0.356 0.438 0.295 NA 0.539 0.438 0.662 ,0.0001
rs3092945 F T C 0.334 0.387 0.285 0.3588 0.631 0.465 0.856 0.0031
rs3092945 M T C 0.346 0.320 0.365 NA 1.219 0.913 1.627 0.1795
rs3092945 Ov T C 0.338 0.352 0.327 NA 0.893 0.724 1.101 0.2891
rs1126535 F T C 0.128 0.095 0.158 0.5737 1.798 1.157 2.796 0.0092
rs1126535 M T C 0.098 0.077 0.113 NA 1.534 0.954 2.468 0.0776
rs1126535 Ov T C 0.112 0.085 0.134 NA 1.671 1.209 2.309 0.0019
rs1050829 F A G 0.423 0.401 0.443 0.9805 1.188 0.890 1.585 0.2421
rs1050829 M A G 0.418 0.425 0.413 NA 0.954 0.724 1.259 0.7412
rs1050829 Ov A G 0.421 0.413 0.427 NA 1.060 0.868 1.294 0.5673
rs1050828 F G A 0.162 0.146 0.178 0.9615 1.267 0.862 1.861 0.2281
rs1050828 M G A 0.183 0.162 0.198 NA 1.278 0.896 1.824 0.1757
rs1050828 Ov G A 0.173 0.154 0.189 NA 1.273 0.981 1.653 0.0699
MinA=minor allele, MajA =major allele, MAF= overall minor allele frequency, HWE P is the Hardy-Weinberg p-value, OR = odds ratio, 95% Confidence interval (LCL,
UCL), P = P-value; rs8176746 and rs8176719 are used to infer ABO blood groups; for X chromosome SNPs (rs3092945 (CD40), rs1126535 (CD40), rs1050829 (G6PD-376),
rs1050828 (G6PD-202/A-), analyses are presented for separately for females (F) and males (M) and pooled to obtain overall results (Ov), NA not applicable; rs33950507,
rs5743611, rs2814778, rs2227478, rs2535611 and rs1801274 did not pass quality control filters and are not presented.
doi:10.1371/journal.pone.0043987.t002
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effects, especially if relying on markers in LD with a causal
untyped polymorphism. In this setting, dense SNP genome-wide
association strategies are required to discover new candidate
genes.
Our analysis revealed a marginal susceptibility effect for the
CD40 ligand (CD40L)+220C allele. CD40L is a glycoprotein
involved in B cell proliferation, antigen presenting cell activation,
and Ig class switching, and therefore important in the immune
response to infection [13]. Previous work in the Gambia found the
CD40L+220C allele had a non-significant susceptibility effect, and
instead identified the genotyped CD40L–726 polymorphism with
a significant reduction in risk for severe malaria in males-
hemizygous [13]. Similarly, we expected to see a reduced malaria
risk with G6PD-202A (A- deficiency), as shown in another Malian
population [8] with similar allele frequencies in controls to our
study. These discrepancies in CD40L and G6PD results may be
due to allelic heterogeneity. For example, it has been shown that
the G6PD-202 may not be a good marker of A- deficiency, and
other polymorphisms are required to confirm the protective effect
[21]. In addition, discrepancies may arise due to differences in
linkage disequilibrium (LD) patterns between populations. For
example, it is known there are at least five classical haplotypes
surrounding the sickle polymorphism in the HBB gene, and the
resulting differences in LD can make it difficult to localise HbS
using indirect associations [7]. In addition, some functional
polymorphisms may be distal from candidate genes and polymor-
phisms genotyped. For example, it has been suggested that the
causal polymorphisms regulating TNF and LTA response may be
some distance from the genes [11,23].
In conclusion, our work reinforces in a Malian (mainly
Bambara) population the importance of the sickle cell polymor-
phism and ABO blood group on severe malaria susceptibility. It
may also demonstrate the need for establishing the region-specific
repertoire of functional variation in important genes such as
G6PD, before embarking on focused genotyping. Proposed large-
scale genomewide association studies and resequencing of
important genes in a number of Malian (and other African)
Figure 1. Minimum p-values from tests of association for the autosomal SNPs *. *Genotypic tests of dominant, recessive, general,
heterozygous advantage, and additive models, adjusted for HbS and ethnicity; in this analysis controls include uncomplicated malaria cases; the
dashed line represents a p-value of 0.002.
doi:10.1371/journal.pone.0043987.g001
Table 3. Odds ratios* for HbS, ABO, CD40 and G6PD-202.
Polymorphism Contrast OR LCL UCL P
HbS (rs334) AS vs. AA 0.028 0.004 0.209 ,6E-10
Blood Group (rs8176719) O vs. A/B/AB 0.575 0.425 0.777 0.0003
CD40 (rs1126535) – Female Additive C 1.674 1.045 2.683 0.03
CD40 (rs1126535) – Male Additive C 2.119 0.990 4.537 0.05
CD40 (rs1126535) – Overall Additive C 1.787 1.197 2.669 0.0045
G6PD (rs1050828, 202) – Female AG vs. GG 1.187 0.747 1.887 0.467
G6PD (rs1050828, 202) – Female AA vs. GG 1.557 0.427 5.684 0.502
G6PD (rs1050828, 202) – Male A vs. G 1.205 0.718 2.022 0.480
*adjusted for HbS and ethnicity, OR =odds ratio, 95% Confidence interval (LCL,
UCL), P = P-value, in this analysis controls include uncomplicated malaria cases.
doi:10.1371/journal.pone.0043987.t003
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populations is likely to generate insights into how P. falciparum has
shaped our genome. These approaches could expose new
candidate protective polymorphisms, resulting in functional work
to understand underlying molecular mechanisms, leading to the
development of therapies and vaccines for malaria control.
Supporting Information
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